Clay Siegall Finds a Cure


Posted by LLJ43 | Posted in Science | Posted on 05-11-2017

The chairman, president, CEO, and cofounder of Seattle Genetics, Clay Siegall, has large ambitions when it comes to the business of oncology and is committed to obtaining the rights of new drugs in order to distribute them to a larger, global market. Seattle Genetics is already the largest biotech in the state of Washington with its most important drug being Adcetris, which treats Hodgkin lymphoma, and if proven effective the sales could sky rocket. Siegall hopes to handle every aspect of marketing for his newer drugs which is why he opened an office in Switzerland to deal internationally.

Siegall’s approach is vastly different from that traditional cancer treatment. Seattle Genetics focuses on the ADC drug; the antibody-drug conjugate targets antigens which are protein molecules that cause an immune system to develop antibodies. The drug attaches itself to the outside of the cancer cell and delivers a toxin to kill the cell entirely. Unlike radiation and chemotherapy, ADC drugs do not harm normal tissues. Although Seattle Genetics has not seen a profit yet, with this approach, they are sure to market a vast amount of sales in the future.

Clay Siegall studied at the Bristol-Myers Suibb Pharmaceutical Research Institute before co-founding Seattle Genetics, and before that the National Cancer Institute as well as the National Institutes of Health. He is a member of the Board of Directors of Alder BioPharmaceuticals which is a private biotechnology company and has proven his determination for solidifying a global presence in the marketing of ADC drugs. A biopharmaceutical company known as Ultragenx that focuses on developing products for rare diseases appointed Clay Siegall to the company’s Board of Directors in 2014. Siegall is expected to serve as an independent director along with Matthew Fust, former Executive Vice President of Onyx Pharmaceuticals, proving his expertise in the field of biotechnology.

Write a comment

You must be logged in to post a comment.